Email updates

Keep up to date with the latest news and content from BMC Pharmacology and Toxicology and BioMed Central.

This article is part of the supplement: 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR)

Open Access Meeting abstract

Uremia alters HDL composition and cholesterol efflux capacity

Michael Holzer1, Ruth Birner-Grünberger2, Tatjana Stojaković3, Dalia El-Gamal1, Veronika Binder1, Christian Wadsack4, Ákos Heinemann1 and Gunther Marsche1*

Author Affiliations

1 Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 8010 Graz Austria

2 Proteomics Core Facility, Centre for Medical Research, Medical University of Graz, 8036 Graz, Austria

3 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria

4 Department of Obstetrics and Gynecology, Medical University of Graz, 8036 Graz, Austria

For all author emails, please log on.

BMC Pharmacology and Toxicology 2012, 13(Suppl 1):A15  doi:10.1186/2050-6511-13-S1-A15


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/2050-6511/13/S1/A15


Published:17 September 2012

© 2012 Holzer et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Functional impairment of HDL may contribute to the excess cardiovascular mortality experienced by patients with renal disease, but the effect of advanced renal disease on the composition and function of HDL is not well understood.

Methods

Mass spectrometry and biochemical analyses were used to study alterations in the proteome and lipid composition of HDL isolated from patients on maintenance hemodialysis.

Results

We identified a significant increase in the amount of acute-phase protein serum amyloid A1, albumin, lipoprotein-associated phospholipase A2, and apoC-III composing uremic HDL. Furthermore, uremic HDL contained reduced phospholipids and increased triglycerides and lysophospholipids. With regard to function, these changes impaired the ability of uremic HDL to promote cholesterol efflux from macrophages.

Conclusions

In summary, the altered composition of HDL in renal disease seems to inhibit the cardioprotective properties of HDL. Assessing HDL composition and function in renal disease may help to identify patients at increased risk for cardiovascular disease.

Acknowledgements

This work was supported by the Austrian Science Fund FWF (grants P21004-B02 and P22976-B18).